DC Circ. Won't Revisit Eagle's Orphan Drug Win Against FDA
The full D.C. Circuit on Monday stood by a three-judge panel's recent ruling concluding that multiple manufacturers of a drug that treats the same rare medical condition are entitled to marketing...To view the full article, register now.
Already a subscriber? Click here to view full article